



## **Prototype professional EEG recording system Mente Pro unveiled at international brain stimulation congress**

- *Mente Pro, with the embedded Mente Suite software, to provide greater flexibility and capability to medical professionals*
- *Modular solution for hospital or clinical settings to address a range of diagnostics and therapies*

**Perth, Australia & Malta – 9 March 2017** – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), developer of quality medical solutions in the neuroscience space, has unveiled the prototype of its new professional EEG recording system Mente Pro.

Designed with the medical professional and clinical/hospital settings in mind, the prototype was presented to medical professionals at the 2<sup>nd</sup> International Brain Stimulation Conference in Barcelona, Spain. The four-day conference attracts leading experts in brain stimulation and neuroscience from around the world.

Mente Pro is a 32-channel EEG headset with a modular software solution known as Mente Suite. The system enables medical professionals, hospitals and/or clinics to monitor or treat patients with three significant advantages:

- Consolidation of hardware – Mente Pro will provide the professional with the ability to perform a number of tests and/or treatments using just one device, where as previously this would have required numerous pieces of hardware and technology
- Personalisation – when combined with the Mente Suite software, patients will receive personalised treatments based upon individual circumstances and historical data
- Modular system – the Mente platform will enable the professional to add additional capabilities or treatments, known as modules, with ease using the existing hardware. Neurotech’s aim is to develop the system to be beneficial across various neurological disorders

By allowing the medical professional the ability to provide various non-invasive tests and treatments, such as Transcranial Electrostimulation (tES) and neurofeedback, Mente Pro is a highly flexible and scalable platform. The option to combine this with personal patient data is an important differentiating factor.

Mente Pro meets all the specifications and requirements for the administration of routine EEG recording and long-term monitoring in hospitals and clinics. It also offers all the parameters and clinical indicators to detect neurological diseases and pathological abnormalities by experts in an easy to use, integrated solution.

Mente Suite creates an innovative method to administer both neurofeedback and tES, using a model that allows the use of personalised MRI and DTI data of an individual patient , to conduct both EEG

---

### **Neurotech International Ltd**

ABN 73 610 205 402

Level 14, 191 St Georges Terrace


Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

monitoring and tES in real-time, a market first. It offers a unique, efficient way to record, analyse and provide brain stimulation for therapeutic and/or research purposes through the same software.

Neurotech founder and Chief Scientific Officer Dr Adrian Attard Trevisan said: “Mente Pro and the software element Mente Suite is more than an EEG recording system. The design, modularity and unique feature set in the product address the needs of medical professionals who require a complete system that is scalable and enables them to provide neurofeedback therapies and the management of tES protocols.

“The beauty of the system is that in future, when combined with Mente Suite, it gives medical professionals the ability to add modules for other diagnostics / therapies without the need for additional hardware or software.”



Neurotech CEO Wolfgang Storf said: “Presenting the prototype for Mente Pro and Mente Suite at the Brain Stimulation Conference is an important milestone for the company as we will be able to enter the B2B space with a unique offering for medical professionals and hospitals. The modularity and scalability of the product enables us to build out the system and create new commercial opportunities.”

Dr Attard Trevisan presented a paper at the conference entitled: Towards a personalised model for transcranial direct current stimulation (tDCS). This represents a valuable first step in very rapidly and specifically mapping out areas of the brain to be stimulated on an individual basis, otherwise a key limitation of existing generic mapping models.

#### **Wi-Fi connectivity available for Mente Autism users**

Neurotech has also announced that Mente Autism users can now connect their device using a home or guest Wi-Fi connection, in addition to a 3G/4G hotspot.

This connectivity option allows Mente Autism users to connect the device to any Wi-Fi service (provided they have the necessary access) without the need for a mobile data package.

Neurotech will ship the first Wi-Fi enabled units this week.

Dr Adrian Attard Trevisan said: "This is an important update for the Mente Autism system and addresses one of the primary requests we received from distribution partners and users. Customers using Mente Autism now have the option to connect to the device using either a Wi-Fi connection or a 3G/4G hotspot. This gives increased mobility to users in that they are not limited to one connectivity method and they can synchronise and upload session data with greater ease."

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

-ends-

### **About Neurotech**

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: <http://www.neurotechinternational.com>.

*For more information please contact:*

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420